SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

Rhea-AI Summary

SOPHiA GENETICS (Nasdaq:SOPH) priced a public offering of 10,526,000 ordinary shares at $4.75 per share, targeting gross proceeds of approximately $50 million before fees. All shares are issued by the company, with underwriters holding a 30-day option to buy up to 1,578,900 additional shares. The offering is expected to close on June 18, 2026, subject to customary conditions.

Positive

• Planned gross proceeds of approximately $50 million before fees
• Underwriters’ 30-day option for up to 1,578,900 additional shares may increase proceeds
• Offering supported by multiple underwriters, led by TD Cowen

Negative

• Issuance of 10,526,000 new shares dilutes existing shareholders
• Underwriters’ option for 1,578,900 extra shares could add further dilution

News Market Reaction – SOPH

+6.29% 2.0x vol

8 alerts

+6.29% Session close to close

+21.8% Peak in 17 hr 35 min

$393.41M Market Cap

2.0x Rel. Volume

In the Jun 17 session, SOPH gained 6.29%, reflecting a notable positive market reaction. Argus tracked a peak move of +21.8% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the company’s need to access capital but would stand in tension with the dilutive nature of issuing 10,526,000 new shares at $4.75. Historically, SOPH has often traded lower after news, so a sharp gain could reflect short-term positioning or enthusiasm about balance-sheet strengthening. Investors would still need to monitor follow-on usage of the effective F-3 program and any additional offerings.

Key Figures

Offering size: 10,526,000 ordinary shares Offering price: $4.75 per share Gross proceeds: Approximately $50 million +5 more

8 metrics

Offering size 10,526,000 ordinary shares Underwritten public offering at fixed price

Offering price $4.75 per share Public offering price for ordinary shares

Gross proceeds Approximately $50 million Before underwriting discounts and expenses

Underwriter option 1,578,900 additional shares 30-day option at offering price, less discounts

Shares outstanding 71,790,366 shares Ordinary shares outstanding as of Mar 31, 2026 (424B5)

Last Nasdaq sale price $5.01 per share Last reported sale on Jun 15, 2026 (424B5)

Warrant exercise price $5.1829 per share Second Amendment warrant shares under F-3 shelf

Potential warrant proceeds $388,717.50 If all 75,000 Second Amendment warrant shares exercised

Historical Context

5 past events · Latest: Jun 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 10	Leadership transition	Neutral	-3.3%	Announced CEO change and board role shifts ahead of AGM.
Jun 04	Strategic partnership	Positive	+3.8%	MOU with Memorial Sloan Kettering for precision oncology joint venture.
May 13	Commercial partnership	Positive	-2.6%	Synnovis deal to expand MSK-ACCESS® blood-based cancer testing in the U.K.
May 05	Earnings release	Neutral	-4.2%	Q1 2026 results with 22% revenue growth and reaffirmed guidance.
Apr 21	Earnings schedule	Neutral	-1.4%	Announcement of timing and webcast details for Q1 2026 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across the last five news events, SOPH traded down after four of them, suggesting a tendency for negative short-term reactions to announcements, including partnerships and earnings.

Recent Company History

Over recent months, SOPH has announced board and leadership changes (Jun 10, 2026), multiple precision-oncology collaborations (Jun 4 and May 13, 2026), and Q1 2026 results with $21.7M revenue and reaffirmed guidance. Despite strategically positive items like new partnerships and record SOPHiA DDM™ analyses, four of the last five releases saw negative 24-hour price reactions, framing today’s dilutive offering against a backdrop of generally cautious trading around news.

Key Terms

underwritten public offering, public offering price, underwriters, prospectus supplement, +3 more

7 terms

underwritten public offering financial

"announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

public offering price financial

"ordinary shares at a public offering price of $4.75 per ordinary share"

The public offering price is the amount of money a company charges investors to buy its shares during a new stock sale to the public. It determines how much the company raises and how much each share is worth at the start of trading. For investors, it helps gauge the initial value of the stock and whether it might be a good investment opportunity.

underwriters financial

"the Company has granted the underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares"

Underwriters are financial professionals or institutions that help companies raise money by selling new securities, such as stocks or bonds, to investors. They assess the risk and determine the price at which these securities should be sold, acting like a bridge between the company and the investors. Their role helps ensure that the company raises the needed funds while providing investors with options that reflect the level of risk involved.

prospectus supplement regulatory

"The offering may be made only by means of a prospectus supplement and accompanying prospectus."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

form f-3 regulatory

"A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

regulated trading venue regulatory

"not be listed or admitted to trading on the SIX Swiss Exchange or on any other regulated trading venue"

A regulated trading venue is an exchange or electronic marketplace that operates under government or financial-authority rules to buy and sell stocks, bonds or other securities. Like a licensed marketplace with clear entry rules, price reporting and oversight, it reduces the risk of fraud and sudden trading halts, so investors can trust that trades are executed fairly and prices reflect transparent supply and demand — which protects capital and supports reliable valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company are expected to be approximately $50 million. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,578,900 additional ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on June 18, 2026, subject to customary closing conditions.

TD Cowen is acting as the lead book-running manager for the offering. Guggenheim Securities is acting as book-running manager, and BTIG and Craig-Hallum are acting as lead managers for the offering.

A registration statement on Form F-3 (File No. 333-289266) relating to the ordinary shares and other securities of the Company has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on August 15, 2025. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus will be available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained for free by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of SOPHiA GENETICS SA, such as the ordinary shares, in or into Switzerland within the meaning of the Swiss Financial Services Act ("FinSA") and these securities will not be listed or admitted to trading on the SIX Swiss Exchange or on any other regulated trading venue (exchange or multilateral trading facility) in Switzerland. Neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, constitutes or will constitute a prospectus pursuant to the FinSA, and neither this press release nor any other offering or marketing material relating to these securities, such as the ordinary shares, may be publicly distributed or otherwise made publicly available in Switzerland.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using Ai to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our expectations regarding the expected closing of this offering. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the SEC. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-pricing-of-50-million-public-offering-of-ordinary-shares-302802511.html

SOURCE SOPHiA GENETICS

FAQ

What did SOPHiA GENETICS (Nasdaq:SOPH) announce about its June 2026 stock offering?

SOPHiA GENETICS announced pricing of a public offering of 10,526,000 ordinary shares at $4.75 per share. According to the company, expected gross proceeds are about $50 million before underwriting discounts, commissions, and expenses.

How much money will SOPHiA GENETICS (SOPH) raise from the June 2026 share offering?

The company expects to raise approximately $50 million in gross proceeds from the offering. According to SOPHiA GENETICS, this figure is before deducting underwriting discounts, commissions, and estimated offering expenses payable by the company.

What is the share price and size of the SOPHiA GENETICS (SOPH) public offering?

The public offering is priced at $4.75 per ordinary share for 10,526,000 shares. According to SOPHiA GENETICS, all offered shares are being sold by the company, with potential additional shares via an underwriters’ option.

When is the SOPHiA GENETICS (SOPH) stock offering expected to close?

The offering is expected to close on June 18, 2026, subject to customary closing conditions. According to SOPHiA GENETICS, completion depends on standard requirements typically applied in underwritten public offerings.

How does the SOPHiA GENETICS (SOPH) offering affect existing shareholders?

The issuance of 10,526,000 new shares will dilute existing shareholders’ ownership percentage. According to the company, underwriters also have a 30-day option to purchase up to 1,578,900 additional shares, which could further increase dilution.

Do underwriters have an over-allotment option in the SOPHiA GENETICS (SOPH) offering?

Yes, underwriters have a 30-day option to buy up to 1,578,900 additional ordinary shares at the offering price. According to SOPHiA GENETICS, this option is at $4.75 per share, less underwriting discounts and commissions.

Who are the underwriters for the SOPHiA GENETICS (SOPH) June 2026 share sale?

TD Cowen is the lead book-running manager, with Guggenheim Securities as book-runner and BTIG and Craig-Hallum as lead managers. According to SOPHiA GENETICS, these firms are managing the underwritten public offering process.